Proprietary Drug Delivery Platforms: Alkermes possesses advanced and proprietary drug delivery technologies, particularly for long-acting injectable medications, which allow them to create differentiated products with improved patient adherence, efficacy, and safety profiles compared to daily oral treatments.

Focused Therapeutic Area Expertise: The company specializes in central nervous system (CNS) disorders (e.g., schizophrenia, bipolar I disorder, depression, addiction) and oncology, enabling deep scientific and commercial expertise, more targeted R&D, and stronger relationships within these medical communities.

Established Commercial Product Portfolio: Alkermes has a portfolio of approved and commercialized products such as Aristada, Lybalvi, and Vivitrol, which generate significant and stable revenue streams, funding ongoing research and development efforts and supporting market presence.